•
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase III TORCHLIGHT study for its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab). The study, which combines Tuoyi with paclitaxel and albumin, has completed its pre-set interim analysis for initially-diagnosed stage IV or recurrent metastatic triple-negative breast…
•
US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical Device Co., Ltd. The collaboration aims to leverage the respective strengths of both companies in technology, service network, and other areas to enhance the distribution of advanced medical technologies and solutions in China. Partnership Scope…
•
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted a filing for another indication approval for its potassium-competitive acid blocker (P-CAB), tegoprazan. The drug is being reviewed for the treatment of duodenal ulcers, expanding…
•
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products Administration (NMPA) has accepted a market approval filing for its Category 1 gastric acid blocker, X842. The targeted indication for this innovative drug is reflux esophagitis (RE), a condition affecting a significant number of patients…
•
We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly secured “tens of millions” of renminbi in an angel financing round. The funding round was led by Bluerun Ventures and CDH Investments, with participation from Naton Technology and Guokr.com. Company Background and AchievementsFounded in 2019,…
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot firm China Resource Medicine Commercial Holdings Ltd. The partnership aims to expand market reach, enhance promotion efforts, and boost sales. Financial details of the agreement were not disclosed. Hybio Pharma’s Strategic LeverageHybio Pharma, a key…
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission of a market approval filing for its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), to the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK. The company is seeking approval for the checkpoint inhibitor in…
•
Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the enrollment and dosing of the first subject in a Phase I/II clinical study for its ophthalmology gene therapy ZVS101e in Tianjin. This study marks the first potentially regulatory clinical trial for a gene therapy targeting…
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical study for its oral double prodrug ASC10. The findings were presented at the CROI 2023 annual meeting, marking a significant step forward in the development of this promising therapeutic candidate. Phase I Clinical Data HighlightsThe…
•
China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly secured an undisclosed amount of angel funding. The round was led by Tus Star, with participation from Wuxi Kelin Venture Capital Partnership. The proceeds will be directed towards accelerating the research and development of pelvic…
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a significant milestone. The company’s generic version of AbbVie’s (NYSE: ABBV) bimatoprost and timolol maleate eye drops has been granted approval in China. This approval is for use in lowering the intraocular pressure of patients…
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug limaprost. This therapeutic drug targets analgesia and microcirculation, addressing a significant health issue among the country’s population. Lumbar Spinal Stenosis: A Prevalent ConditionTubular stenosis, particularly lumbar spinal…
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,” an ambitious initiative designed to develop fully human nanobody drugs for over 100 targets. This project leverages Biocytogen’s proprietary fully human nanobody mouse, RenNano, in conjunction with its high-throughput in vitro and in vivo antibody…
•
Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the US FDA to initiate a Phase I/II clinical study for its BRG01, an autologous T cell therapy for the treatment of relapsed/metastatic nasopharyngeal cancer (NPC). This marks a significant milestone in the development of innovative…
•
The national drug alliance procurement office has released a notification initiating the drug information filing process for the 8th volume-based procurement (VBP) round. This round is a significant step in the ongoing efforts to streamline and optimize the procurement of pharmaceuticals in China. Registration and Information SubmissionAs of February 20,…
•
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major. The company reported the first cure in a multi-center Phase clinical study assessing the safety and efficacy of its BRL-101, an autologous hematopoietic stem progenitor cell therapy. This marks a major milestone in the development…
•
China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for its ICVAX, a therapeutic vaccine against HIV/AIDS, in Shenzhen. This marks a significant step forward in the development of innovative treatments for HIV/AIDS, a condition that affects millions of people globally. Study Design and ObjectivesThe…
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover…
•
China-based Hainan Honz Pharmaceutical Co., Ltd (SHE: 300086) has entered into a three-year partnership with Indonesia’s Global Putra International (GPI). The strategic collaboration is focused on multiple fronts, aiming to expand Hainan Honz’s pediatric and maternity medicines into overseas markets through the Regional Comprehensive Economic Partnership (RCEP) and Hainan free…